Abstract
The article deals with secondary hyperlipoproteinaemias (dyslipidaemias) in patients with chronic kidney disease (CKD), liver disease, and autoimmune rheumatic disease. In the section devoted to CKD, the pathophysiology of existing dyslipidaemia is discussed first, followed by current treatment recommendations, also taking into account end-stage renal disease patients on haemodialysis therapy and after kidney transplantation.
In case of chronic liver disease, the text describes pathophysiology of dyslipidaemia and its treatment in individuals with non-alcoholic fatty liver disease (NAFLD), alcoholic disease, cirrhosis, and after liver transplantation. Regarding autoimmune rheumatic diseases, dyslipidaemia in rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, and systemic sclerosis are mentioned.
The effect of immunosuppressive therapy on lipid parameters is also discussed.